The Top 5 Biosimilar Articles for the Week of June 23

June 27, 2025

Here are the top 5 biosimilar articles for the week of June 23, 2025.

Eye on Pharma: CHMP Aflibercept Decision; Omalizumab Results; Dupilumab Biosimilar Deal

June 26, 2025

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25, 2025

Omalizumab Biosimilar Matches Reference Product in Chronic Spontaneous Urticaria

June 24, 2025

BioRationality: Questioning Experts and Journals Reporting on Biosimilar Bill to Remove Interchangeability

June 23, 2025

Review Confirms Clinical Safety of Sandoz Denosumab Biosimilar vs Originator

December 11th 2024

By Skylar Jeremias

Article

Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and clinical equivalence to reference denosumab (Prolia/Xgeva), supporting its approval and extrapolation to all approved indications.

BioRationality: Withdrawal of Proposed Terminal Disclaimer Rule Spells Major Setback for Biosimilars

December 10th 2024

By Sarfaraz K. Niazi, PhD

Article

The United States Patent and Trademark Office (USPTO)’s withdrawal of its proposed terminal disclaimer rule is seen as a setback for biosimilar developers, as it preserves patent prosecution practices that favor originator companies and increases costs for biosimilar competition, according to Sarfaraz K. Niazi, PhD.

Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration

December 10th 2024

By Skylar Jeremias

Article

Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.

Pertuzumab Biosimilar Shows Promise in HER2-Positive Breast Cancer Treatment

December 9th 2024

By Skylar Jeremias

Article

The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in neoadjuvant treatment of HER2-positive, ER/PR-negative early or locally advanced breast cancer, offering a cost-effective alternative with comparable clinical outcomes.

AI-Powered Solutions for Streamlining Biosimilar Prescribing and Monitoring

December 8th 2024

By Skylar Jeremias

Video

Steve Pickette, PharmD, BCPS, emphasizes that AI can streamline prescribing and formulary management for biosimilars and generics, enhance provider engagement, and improve pharmacovigilance by tracking adoption rates and identifying potential issues.

Similar Persistence Rates Between Adalimumab New Starts, Switched Patients

December 7th 2024

By Deana Ferreri, PhD

Article

A French real-world study found that the adalimumab biosimilar SB5 was effective in treating rheumatic or gastrointestinal immune-mediated inflammatory diseases, showing no loss of disease control in switched patients and similar persistence rates between naive and switched groups.

The Top 5 Biosimilar Articles for the Week of December 2

December 6th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of December 2, 2024.

Switching to Rituximab Biosimilars Is Safe, Effective for Patients With Oncohematological Diseases

December 5th 2024

By Cameron Santoro

Article

Patients with oncohematological diseases switching to rituximab biosimilars experienced similar safety and efficacy, highlighting biosimilars' potential for cost-effective treatment across various medical conditions.

Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts

December 4th 2024

By Skylar Jeremias

Article

Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.

Cost and Efficacy Insights on Infliximab Biosimilars in Pediatric Uveitis

December 3rd 2024

By Skylar Jeremias

Article

The study highlights the safety, efficacy, and cost benefits of infliximab biosimilars in managing pediatric noninfectious uveitis, showing fewer disease flares and reduced costs compared with reference infliximab, as well as the influence of insurance mandates on treatment decisions.